Camilo Montero

Camilo Montero

Auto-generated profile, based on publicly available information

Camilo Montero

Renal Transplantation Group, Clinica Colombia, University Clinic, Bogota, Colombia; Translational Investigation Group, Fundacion Universitaria Sanitas, Bogota, Colombia; Renal Transplantation Group, Hospital de San Jose, University Hospital, Bogota, Colombia; Renal Transplantation Group, Clinica del Country, Bogota, Colombia

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 September 2022 in Nefrología
Verified
Journal Article
Open access
CMCamilo Montero
Camilo Montero
RTRodolfo Torres
Rodolfo Torres
CBCarlos Benavidez
Carlos Benavidez
PGPaola Garcia
Paola Garcia
SJSandra Jimenez
Sandra Jimenez
CACarlos Alvarez-Moreno
Carlos Alvarez-Moreno
The impact of immunosuppression in solid organ transplant recipients with SARS-CoV-2 infection is unknown. The knowledge about the behavior of different immunosuppression schemes in clinical outcomes is scarce. This study aimed to determine the risk of death in kidney transplant recipients with COVID-19 under two different schemes of immunosuppression. We describe our experience in kidney transplant recipients with SARS-CoV-2 infection in seven transplant centers during the first year of the pandemic before starting the vaccination programs in the city of Bogotá. Demographic characteristics, clinical presentation, immunosuppression schemes at presentation, and global treatment strategies were compared between recovered and dead patients; survival analysis was carried out between calcineurin inhibitors based regimen and free calcineurin inhibitors regimen. Among 165 confirmed cases, 28 died (17%); the risk factors for mortality identified in univariate analysis were age older than 60 years (p = .003) diabetes (p = .001), immunosuppression based on calcineurin inhibitors (CNI) (p = .025) and patients receiving steroids (p = .041). In multivariable analysis, hypoxemia (p = .000) and calcineurin inhibitors regimen (p = .002) were predictors of death. Survival analysis showed increased mortality risk in patients receiving CNI based immunosuppression regimen vs. CNI free regimens mortality rates were, respectively, 21.7% and 8.5% (p = .036). Our results suggest that the calcineurin inhibitors probably do not provide greater protection compared to calcineurin inhibitor free schemes being necessary to carry out analyzes that allow us to evaluate the outcomes with different immunosuppression schemes in solid organ transplant recipients with SARS-CoV-2 infection.

25 November 2022 in Nefrología (English Edition)
Verified
Journal Article
Open access
CMCamilo Montero
Camilo Montero
NYNancy Yomayusa
Nancy Yomayusa
RTRodolfo Torres
Rodolfo Torres
JCJorge Cortes
Jorge Cortes
CACarlos Alvarez
Carlos Alvarez
MIMilciades Ibanez
Milciades Ibanez
We performed a retrospective trial to determine asymptomatic CMV reactivation and CMV disease in kidney allograft recipients with positive CMV serostatus. Preemptive modified strategy under low dose thymoglobulin versus basiliximab induction was evaluated. Patients were monitored by CMV-polymerase chain reaction (PCR); if the viral load was >4000copies/μl, they received valganciclovir adjusted for their renal function. 132 recipients were included in the study, 84 and 48 receiving basiliximab and thymoglobulin induction respectively, and followed up for 12 months. Asymptomatic CMV reactivation was significantly higher for thymoglobulin (77.1% vs. 16.7%, p<0.001). Treatment groups had similar rates of CMV disease (3.6% vs. 2.1%, p 0.538). The significant difference in asymptomatic CMV reactivation between two treatment groups did not have any impact on 1 year graft function (71±26ml/min vs. 74±19ml/min; p=0.475) and no histological differences in protocol biopsies were observed among patients with asymptomatic CMV reactivation vs those without CMV reactivation. Due to the high asymptomatic CMV reactivation incidence in patients who received thymoglobulin induction, our results suggest that valganciclovir prophylaxis may be advantageous in CMV seropositive renal transplant recipients after low dose thymoglobulin induction. A preemptive strategy appeared to significantly reduce the likelihood of CMV disease in both groups. Rejection risk and negative impact in renal function associated with asymptomatic CMV reactivation was not found in our series.

19 August 2023 in Journal Of Nephrology
Verified
Journal Article
Closed access
PDF file
CMCamilo Montero
Camilo Montero
RTRodolfo Torres
Rodolfo Torres
MRMaricely Reina
Maricely Reina
JFJonth Flechas
Jonth Flechas
DADavid Andrade
David Andrade
LQLuis F. Quintana
Luis F. Quintana

7 October 2022 in Revista Colombiana de Nefrología
Verified
Journal Article
Open access
PDF file
RTRodolfo Eduardo Torres-Serrano
Rodolfo Eduardo Torres-Serrano
JCJairo Camilo Montero Cetina
Jairo Camilo Montero Cetina
EOEdwar Ferney Ortiz-Henao
Edwar Ferney Ortiz-Henao
GPGloria Constanza Pastrana-Mejía
Gloria Constanza Pastrana-Mejía
LSLarry Salamanca-Rodríguez
Larry Salamanca-Rodríguez
Introducción: el sarcoma de Kaposi en pacientes de postrasplante renal es poco frecuente y está asociado usualmente a infección por herpes 8 y a dosis altas de inmunosupresión. Objetivo: descripción reporte de caso de Sarcoma de Kaposi en orofaringe en paciente postrasplante renal manejo con inhibidor de señal de coestimulación e inhibidor mTOR. Presentación del caso: en este artículo se describe el caso de una paciente, con antecedente de trasplante renal, con diagnóstico de sarcoma de Kaposi en una localización muy poco frecuente: a nivel orofaríngeo. Se realiza una revisión de los factores de riesgo, patogenia y un acercamiento en el manejo. De igual manera, se realiza un seguimiento y manejo con inhibidor de señal de coestimulación (belatacept) e inhibidor de mTOR. Discusión y conclusión: el sarcoma de Kaposi es una de las neoplasias postrasplante con mayor incidencia comparativamente con la población no trasplantada, donde el papel de la reactivación de la infección viral, más el papel de la inmunosupresión, son puntos fundamentales en la génesis de la neoplasia. La determinación del estatus serológico IgG para HHV8 podría ser una estrategia de determinación del riesgo en el pretrasplante.

10 September 2024 in Brazilian Journal of Microbiology
Verified
Journal Article
Closed access
PDF file
YAYazmin R. Arias-Murillo
Yazmin R. Arias-Murillo
MSMaría A. Salinas-N
María A. Salinas-N
CMCamilo Montero
Camilo Montero
FGFernando Giron
Fernando Giron
MMMarcela Mercado-Reyes
Marcela Mercado-Reyes

12 October 2026 in IDCases
Verified
Journal Article
Open access
JGJavier Garzón
Javier Garzón
CDCándida Diaz-Brochero
Cándida Diaz-Brochero
TOTatiana Ordoñez
Tatiana Ordoñez
JBJuan Sebastián Bravo
Juan Sebastián Bravo
MLMaria Jose López
Maria Jose López
RTRodolfo Torres
Rodolfo Torres
Bartonella species are increasingly recognized as causes of invasive infections in immunocompromised hosts. We report the first case in Colombia of disseminated Bartonella washoensis infection in a kidney transplant recipient. A 43-year-old woman receiving maintenance immunosuppression presented with prolonged fever, constitutional symptoms, abdominal pain, multiple splenic lesions, and vertebral osteomyelitis. Extensive microbiological, serological, and molecular investigations were initially negative. Due to persistent fever and diagnostic uncertainty, a diagnostic splenectomy was performed, which revealed necrotizing granulomas. Broad-range bacterial 16S rRNA next-generation sequencing of splenic tissue identified B. washoensis, establishing the diagnosis of disseminated bartonellosis. Targeted antimicrobial therapy resulted in clinical and radiological improvement without recurrence during follow-up. This case highlights the potential for rare zoonotic Bartonella species to cause disseminated disease in transplant recipients and underscores the diagnostic value of broad-range bacterial 16S rRNA amplicon sequencing when conventional diagnostic methods are unrevealing.